Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Average Target Price from Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLIGet Free Report) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $40.40.

DNLI has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday. Finally, Jefferies Financial Group boosted their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st.

View Our Latest Stock Analysis on DNLI

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $21.43 on Monday. The company has a market cap of $3.08 billion, a price-to-earnings ratio of -7.76 and a beta of 1.35. The stock’s fifty day moving average price is $26.14 and its two-hundred day moving average price is $24.92. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) earnings per share. On average, equities analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 86,578 shares of company stock worth $2,474,440 over the last 90 days. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Hedge funds have recently modified their holdings of the business. CWM LLC grew its holdings in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC purchased a new position in Denali Therapeutics in the third quarter worth about $73,000. Assetmark Inc. grew its stake in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after purchasing an additional 920 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $194,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

(Get Free Report

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Featured Articles

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.